PDC/PDCX-based and pathological analyses of RCC uncovered that NRN1 and its co-expressing molecule CXCR4 are positively associated with RCC patient prognosis and their silencing substantially suppresses PDC viability and PDCX tumor growth. This evidence concerns the gene CXCR4 and renal cell carcinoma.